HIGH-RISK, BCG-NAÏVE NON-MUSCLE-INVASIVE BLADDER CANCER
Clinical trials for HIGH-RISK, BCG-NAÏVE NON-MUSCLE-INVASIVE BLADDER CANCER explained in plain language.
Never miss a new study
Get alerted when new HIGH-RISK, BCG-NAÏVE NON-MUSCLE-INVASIVE BLADDER CANCER trials appear
Sign up with your email to follow new studies for HIGH-RISK, BCG-NAÏVE NON-MUSCLE-INVASIVE BLADDER CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy shows promise in bladder cancer fight
Disease control OngoingThis study tests whether adding the immunotherapy drug durvalumab to standard BCG treatment helps keep high-risk bladder cancer from coming back. About 1,000 adults with non-muscle-invasive bladder cancer who have not had BCG before will receive either the combination or BCG alon…
Matched conditions: HIGH-RISK, BCG-NAÏVE NON-MUSCLE-INVASIVE BLADDER CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New drug combo aims to keep bladder cancer from coming back
Disease control OngoingThis phase 3 trial tests whether adding the immunotherapy drug sasanlimab to standard BCG treatment helps control high-risk non-muscle invasive bladder cancer better than BCG alone. Over 1,000 participants are enrolled, with some receiving the combination and others BCG only. The…
Matched conditions: HIGH-RISK, BCG-NAÏVE NON-MUSCLE-INVASIVE BLADDER CANCER
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC